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9ion. The girl underwent successful surgery and is doing w
ear after the resection. Sinus tachycardia and PVC wer
onger recorded after surgery, suggesting a cause and e
elationship between the aneurysm and the arrhythmias.
The pathologic study showed a mucus-filled bronchogenic 
f approximately 1 cm in its greatest diameter. The cyst
ocated within the wall of the aneurysm. The cyst lining was 
iliated, columnar of respiratory type, and in part polypty
ubical, with interposed mucous cells and foci of squamous m
lasia with mild lymphocyte infiltrates. Irregular bundles 
mooth muscle cells were present in the thickness of the cys
Figure 1, B, F ).
iscussion
he bronchogenic cyst was a non-expected finding at the p
ogic study of the removed aneurysm that constituted the m
esion. This case documents the possible presence of a bron
enic cyst within the wall of an aneurysm of the pars membrana-
ea septi.
Prior reported cases are different from the present one bec
he bronchogenic cysts were large enough to be detected as 
t the echocardiography or computed tomography scan study.1-5 In
ur patient the lesion diagnosed with echocardiography waseith Hebert, BS, and Nader Moazami, MD, St Louis, Mo
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id not influence the echocardiography diagnosis and the sur
ecision.
A bronchogenic cyst is a benign lesion. Surgical treatme
ontroversial,2 especially in patients without clinical symptom
owever, the benignant nature of the cyst is unknown b
athologic examination. Moreover, the cyst may progressiv
nlarge1 because of mucus accumulation and inflammation of 
all. Analogously to other cardiac masses, it may trigger co
ations such as arrhythmias, conduction disturbances, obstruct
f blood flow, or embolization.2-4
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LViventricular pacing, or chronic resynchronization th
apy (CRT), has been increasingly used in managem
of patients with class III to IV heart failure who
evidence of interventricular conduction delay. Desp
he widespread use of this therapy, the endocardial proce
equired for left ventricular (LV) lead placement can be 
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ntensive and fails in approximately 10% of patients.1,2 In fact, th
V lead placement in the Multicenter InSync Randomized Cli
valuation (MIRACLE) trial was associated with the highest 
f complication.1 Large number of patients undergoing card
urgery have some degree of systolic dysfunction in conjunc
ith interventricular conduction delay. Prophylactic epicardial 
ead placement in this setting may be beneficial and can be per-
ormed with ease. In the absence of any trials showing the bene-
cial effects of prophylactic LV lead placement during cardiac
urgery, we sought to perform a subgroup analysis of the Multi-
enter InSync Implantable Cardioverter-Defibrillator (ICD) Ran-
omized Clinical Evaluation (MIRACLE-ICD) trial to determine
hether the beneficial effects of biventricular pacing continue to
e evident in patients who had previously undergone coronary
rtery bypass grafting (CABG).
ethods
review of the raw data from the MIRACLE-ICD trial was
erformed to determine the response to CRT of patients with
oronary artery disease who received biventricular therapy long
ber 2006
a emic
h ork
H jec-
t D)
r rmed
t ospec
t s no
p with
2 to
6
R
M  Me
v years
n and
N es.
D
B rma-
c  the
1 lved
a with
h kers
t
a with
fi evi-
d -
t  and
a
a ben-
e cular
p  in
s iency
o systo
c tria,
f
l, we
d BG
d cohort
o the
c ection
f cation
f iza-
t edict-
a  ad-
d is our
c sub-
g
e
p
d
u
l
c
R
1
2
3
4
5
T
O
M
N
6
O
E
A
Brief Communicationsfter CABG. A subgroup analysis from 363 patients with isch
eart disease enrolled in the MIRACLE-ICD trial (New Y
eart Association [NYHA] functional class III/IV symptoms, e
ion fraction 35%, QRS 130 ms, and indication for IC
evealed 222 (61%) with history of CABG. This subgroup fo
he basis of this analysis. This group of patients had been pr
ively randomly assigned 1:1 to 6 months of CRT versu
acing. From this subset, clinical end points were analyzed 
-sided Student t tests with mean  SD changes from baseline 
 months.
esults
ean age was 69 years, and 92% of the patients were male.
alues were as follows: time from CABG to CRT, 9.2 
umber of vessels bypassed, 3.5; ejection fraction, 21.5%; 
YHA functional class, 2.8. Table 1 summarizes the outcom
iscussion
iventricular pacing has been popularized as a new nonpha
ologic therapy for patients with chronic heart failure. In
980s, interest in pacing therapy for heart failure largely revo
round manipulation of the atrioventricular delay in patients 
eart failure who were implanted with dual-chamber pacema
hat used right atrial and right ventricular leads.3 Shortening the
trioventricular delay appeared to be beneficial in patients 
rst-degree atrioventricular block and in those with Doppler 
ence of presystolic mitral regurgitation.2,4 Early reports of biven
ricular pacing involved epicardial LV leads. In 1994, Cazeau
ssociates and later Foster and colleagues5 investigated pacing
fter CABG. Both groups found that maximal hemodynamic 
fit was derived from a combination of atrial and biventri
acing, especially when ventricles contracted sequentially and
ynchrony. The underlying concept of CRT was that the effic
f the heart as a pump would be increased if the start of 
ould be synchronized by simultaneously pacing the two a
ABLE 1. Clinical outcomes: Changes at 6 months
CRT on (n 
utcome measure Value
innesota Living with Heart Failure
Questionnaire score change
18.4 23.4
YHA functional class 0.6  0.8
-min hall walk (m) 57.6 105.9
xygen consumption (mL/[kg · min]) 0.6 2.6
xercise time (s) 54.4 129.7
ll values are mean  SD.ollowed by the ventricles.
The Journal of Thoracic-
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le
In this subgroup analysis of a randomized, prospective tria
emonstrated that patients who have previously undergone CA
erive benefits from CRT similar to those seen in the large 
f patients in the MIRACLE-ICD trial. More specifically, 
ohort of patients with NYHA class III or IV symptoms, ej
raction no greater than 35%, QRS at least 130 ms, and indi
or ICD demonstrated a predictable benefit from resynchron
ion. Although there may be other groups of patients with pr
ble benefit from an intraoperative lead placement, our data
ress the benefit for this particular cohort at this time. It 
ontention that improvements in functional capacity of this 
roup of patients is a compelling argument in favor of prophylactic
picardial LV lead placement at the time of cardiac surgery. The
otential difficulty of percutaneous lead placement—related to
ifficulties in cannulating the coronary sinus, variable anatomy,
nsuitable target veins, diaphragmatic stimulation, and lead dis-
odgment—can be circumvented if these leads are placed during
ardiac surgery.
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CRT off (n  116)
n Value n P value
94 9.9  19.4 101 .007
93 0.4  0.7 105 .02
87 60.4 122.6 100 .87
72 0.2 3.4 84 .47
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